Supplementary Table 5. Clinical outcomes among NAFLD participants with liver biopsy, stratified by biopsy-confirmed NASH

	No NASH (n=13 studies, 14,570 patients)			NASH (n=16 studies, 9,297 patients)			*P*–value
	Studies	Events/N	Incidence rate per 1,000 person–years	Studies	Events/N	Incidence rate per 1,000 person–years	
Mortality							
All–cause mortality	5	2,885/12,649	10.32 (2.20–18.44)	7	1,644/13,001	23.46 (3.97–42.95)	0.22
CVD–related	2	841/10,857	6.21 (4.07–8.35)	3	392/11,131	6.09 (0.27–11.91)	0.97
Non–liver cancer–related	2	993/10,880	5.19 (0.00–12.02)	2	354/10,880	7.02 (0.86–13.17)	0.70
Liver–related	3	238/11,169	1.40 (0.43.2–2.37)	5	410/11,521	10.20 (1.30–19.11)	0.054
Non–liver cancer	3	1,084/9,450	10.82 (7.68–13.97)	3	465/9,450	13.84 (12.58–15.10)	0.081
Liver–related events							
Any liver event	7	128/12,067	4.18 (0.00–8.41)	10	352/12,614	34.19 (4.44–63.93)	0.050
Fibrosis progression	1	13/118	62.80 (28.66–96.94)	1	17/118	115.65 (60.67–170.62)	0.11
Cirrhosis (compensated + decompensated)	2	14/1,480	5.69 (0.00–15.98)	3	66/1,754	10.80 (1.26–20.34)	0.48
Decompensation	2	6/1,480	2.38 (0.00–6.01)	3	27/1,754	4.58 (2.75–6.40)	0.29
Liver transplant	N/A	N/A	N/A	2	57/273	54.40 (0.00–150.72)	N/A
HCC	3	72/9,450	0.79 (0.61–0.97)	6	136/9,997	14.79 (1.22–28.37)	0.043
Diabetes	3	51/663	18.40 (13.22–23.59)	3	110/663	22.71 (18.46–26.97)	0.21
HLD/DLD	1	29/178	43.52 (27.68–59.36)	1	13/178	39.35 (17.96–60.74)	0.76
CVD	1	4/285	22.88 (0.46–45.31)	2	25/559	16.22 (0.043–32.39)	0.64

NAFLD, non-alcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; CVD, cardiovascular disease; HCC, hepatocellular carcinoma; HTN, hypertension; HLD, hyperlipidemia; DLD, dyslipidemia.

https://doi.org/10.3350/cmh.2023.0426